Introduction
HIV infection is characterized by an initial, occasionally symptomatic acute phase followed by an asymptomatic period of variable length culminating in clinically evident immunodeficiency. Recent findings tying immune activation to disease pathogenesis have focused attention on earlier stages of HIV. A better understanding of factors that influence the precarious immunologic balance during early disease will assist development of targeted interventions, possibly including earlier or individualized timing of antiretroviral therapy (ART).
Immune activation as the protagonist in HIV immunopathogenesis
Persistent immune activation is manifested by increased turnover of T cells, monocytes and natural killer (NK) cells, high levels of CD4 and CD8 T-cell apoptosis and polyclonal B-cell activation with hypergammaglobulinemia [1] [2] [3] [4] [5] [6] [7] [8] . Immune activation is strongly predictive of HIV disease progression, even when measured prior to seroconversion [9, 10] . Recent studies showing that interleukin (IL)-6, D-dimer and changes in C-reactive protein (CRP), all biomarkers associated with inflammation, predict mortality in HIV-positive patients further revitalized interest in immune activation [11] . The specifics of how HIV hijacks the immune system into a perpetual cycle of activation and failure of viral control remain unclear.
The central role of immune activation in HIV pathogenesis has been demonstrated in studies of sooty mangabeys and African green monkeys (AGMs), the natural hosts of simian immunodeficiency virus (SIV) infection. Sooty mangabeys develop high levels of SIV viremia without CD4 T-cell losses or clinical disease. In contrast, rhesus macaques have lower or similar levels of SIV viremia but develop progressive CD4 T-cell loss leading to clinical manifestations similar to AIDS. The most evident difference between pathogenic (rhesus macaques) and nonpathogenic (sooty mangabeys and AGMs) SIV infection is the lack of immune activation in the latter [12] .
Markers of immune activation in HIV include CD38 [13] , human leukocyte antigen DR (HLA-DR) [14] , CD71 [9] , intracellular Ki67 expression [3, 7, 15] , total CD8 T-cell counts and serum immunoglobulins [16, 17] , serum b2-microglobulin, soluble IL-2 receptor and neopterin [1, 18, 19] . Although many studies have found associations between immune activation and levels of HIV viremia [4, 20] , immune activation can be a stronger predictor of disease progression [1, 13, 18, [21] [22] [23] . In one recent study [24 ] , elite controllers (patients with plasma HIV RNA levels below the limit of detection in the absence of ART) with evidence of CD4 T-cell depletion had elevated levels of predominantly CD8 T-cell activation compared with controls or HIV-positive patients on ART. In contrast, patients with idiopathic CD4 lymphopenia (ICL) who have low CD4 T-cell counts in the absence of HIV show evidence of immune activation in CD4 but not CD8 T cells [25 ] . These studies [15,25 ,26] suggest that CD4 T-cell activation may be at least partly related to lymphopenia-driven T-cell proliferation. Regardless of the stimulus, the presence of activated CD4 T cells appears to be essential for viral replication [27 ] .
Continuous CD4 T-cell loss and replenishment eventually leads to immunodeficiency as the regenerative capacity of weary naïve and central memory cells gradually dwindles despite apparent excess of homeostatic cytokines in the peripheral blood and lymphoid tissue [28] [29] [30] [31] . This exhaustion of the T-cell 'supply' may be due to direct killing by the virus, virus-induced apoptosis, immunologic senescence, the architectural destruction of lymphoid organs from fibrosis induced by transforming growth factor beta (TGF-b) and other cytokines [32, 33] that may interfere with dendritic-T-cell interactions and access to homeostatic cytokines, or a combination of any of these factors.
The current review addresses the different factors that determine the immunologic juncture at which the battle with HIV is lost and immunodeficiency ensues. We propose that some of these factors may become useful in assessing the 'immune profile' or 'immune score' of patients with asymptomatic HIV infection. Assessment of the immune score combined with age, genetic profiling [34] [35] [36] [37] and comorbidities, such as cardiovascular disease or diabetes, could guide individualized therapeutic strategies prior to clinical manifestations of HIV immunodeficiency.
Gut: the veiled site of HIV pathogenesis
The gut is a key site of HIV infection and pathogenesis. Epithelial injury and CD4 T-cell loss in the gut during acute infection may lead to dissemination of microbial products that fuel immune activation. Acute HIV infection results in enterocyte apoptosis and dysfunction, defects in mucosal repair and earlier and more massive depletion of mucosal CD4 T cells [38, 39] Several factors limit the execution and interpretation of studies involving the gut mucosa: the invasive nature of biopsies, differences in selection of biopsy sites, differences in methodology (flow cytometry or immunohistochemistry) and limited sampling material. A harmonized approach to studying the gut mucosa and measuring or estimating total body and total gut CD4 T cells would greatly advance this field.
The elusive role of regulatory T cells in HIV infection
The role of regulatory T cells (Tregs) in HIV disease progression is still unclear. As Tregs are capable of suppressing T-cell activation, they could be of either benefit (suppressing overactivation, diminishing 'bystander apoptosis' and T-cell loss) or harm ( Accumulation of Tregs has been reported in the lymph nodes [61] and gut of viremic patients [62] . After ART, gut Tregs appear to return to normal, suggesting that accumulation in tissues is related to HIV replication [62] . In AGMs, an immediate emergence of Tregs is seen during acute SIV (nonpathogenic) infection, with concomitant TGF-b production dampening T-cell activation [63] . In pigtail macaques, Tregs are depleted in the lamina propria shortly after pathogenic SIV infection but are maintained or expand in peripheral blood and lymph tissue [64, 65] [66] ; functional studies are difficult to perform because of cell number limitations; and sampling of peripheral blood, which contains less than 5% of the lymphocyte population, may be suboptimal because of sequestration in lymphoid tissue. Considering the technical difficulties of studying small subsets of CD4 T cells in patients with significant CD4 lymphopenia, further Treg studies will depend on identification of markers that reliably predict function. Nevertheless, current evidence supports a potentially beneficial role of Treg in containing immune activation in HIV/SIV infection.
The decisive role of type I interferons in chronic HIV infection
In viral infections, type I interferons contribute to direct antiviral activity and maturation of effector T cells [67, 68] . Type I interferons also promote apoptosis of infected cells and suppress T-and B-cell development of mice in the thymus and bone marrow predominantly by interfering with IL-7 signaling [69] [70] [71] . IFNa is involved in the activation of T, NK and B-cell subsets and appears to be a significant link between innate and adaptive immunity in HIV disease pathogenesis [72] . Despite evidence for anti-HIV activity of type I interferons [73, 74] , the innate immune response during HIV infection may be the main driver of immune activation and disease progression [75] . Plasmacytoid dendritic cells (pDCs), in response to HIV virus or particles, produce type I interferons that lead to CD4 T-cell apoptosis via tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and expression of the tryptophan-catabolizing enzyme indoleamine-2,3-doxygenase (IDO). IDO inhibits T-cell receptor (TCR)-triggered T-cell proliferation [76] and can induce differentiation of naïve CD4 T cells into Tregs [77 ] . Boasso et al. [76] showed that T-cell activation occurring within 24 h of in-vitro infection of peripheral blood mononuclear cells (PBMCs), before any HIV-specific response can be generated, is associated with diminished proliferation to TCR signaling and can be reduced by more than 50% when IFNa was blocked. Despite increased circulating IFNa in patients with progressive disease, pDCs from HIV-positive patients demonstrate a blunted interferon response upon stimulation in vitro [78] . This functional exhaustion of pDCs is the consequence of continuous in-vivo stimulation as shown in HIV/hepatitis C virus (HCV) coinfected patients who have diminished in-vitro pDC responses following treatment with exogenous interferon [79] . Supporting evidence comes also from microarray comparisons of activated CD4 T cells from HIV-positive individuals with those from HIV-negative controls confirming markedly greater expression of interferon target genes in HIV [80] .
In early pathogenic SIV infection of macaques, Malleret et al. [81] demonstrated an initial increase in peripheral pDCs, followed by recruitment to lymph tissue and concomitant depletion in peripheral blood. Depletion mirrored increases in plasma SIV-RNA and IFN-I, IDO, IFNg and IL-18 levels. Control of viremia with ART reduced the observed pDC tissue sequestration and dampened cytokine elevation. Consistent with HIV infection, in which IFNa levels correspond to disease progression, SIV-infected rhesus macaques produce significantly higher IFNa levels than sooty mangabeys in response to SIV [82 ] (Fig. 1) . SIV leads to pDC activation via Toll-like receptor (TLR)7 and TLR9 stimulation with subsequent IFNa production in human and rhesus macaque PBMC that is markedly attenuated in sooty mangabeys. This selective lack of innate response to acute SIV infection in sooty mangabeys with muted NK-cell activation, dendritic cell maturation and homing and abrogated INFa but not TNFa response warrants further investigation. These studies have clearly highlighted the role of pDCs and type I interferon in immune activation and their potential as therapeutic targets.
Effective CD8 T cells in HIV infection: a case for strength and youth
The role of CD8 T cells in controlling HIV and SIV viremia has been extensively studied. We selectively review publications of the past year that highlight distinct features of CD8 T cells from LTNPs, the potential role of inhibitory receptors and the presence of autoreactive CD8 T cells in HIV-positive patients.
The degree or polyfunctionality of anti-HIV-specific CD8 T-cell response, as measured by cytokine production, does not predict disease progression [83] . Nonetheless, the CD8 T cells of LTNPs appear to be different than those of progressors. Progressors initially mount a strong polyfunctional anti-HIV CD8 T-cell response but, unlike LTNPs, are unable to sustain it [83] . Previous studies have shown that HIV-specific CD8 T cells from LTNPs were more proliferative in response to HIV peptides or autologous CD4 T-cell targets than those from progressors [84] . Most recently, CD8 T cells from LTNPs were shown to be more effective killers of HIVinfected CD4 T cells by release of perforin and granzyme B [85 ] .
Another study [86] highlighted a different aspect of the CD8 T-cell advantage in elite controllers; telomeres in their HIV-specific CD8 T cells were significantly longer (and telomerase more active) compared with progressors. CD8 T cells that have lost expression of CD27 and CD28 due to repeated stimulation and activation were incapable of reviving telomerase levels but were still capable of producing IFNg and perforin upon stimulation. Thus, loss of telomerase may represent a state of end-stage differentiation and not functional exhaustion [86] . Enhanced T-cell survival after TCR stimulation and gc cytokine signaling was also shown in the memory CD4 T cells of elite controllers compared with both progressors and HIV-uninfected controls and was found to be related to higher levels of phosporylated FOX3a, a transcription factor that has antiproliferative and proapoptotic effects in its unphosphorylated, transcriptionally active form [87 ,88] . Blocking FOXO3a by siRNA in this study [87 ] improved T-cell survival after TCR stimulation.
Programmed death receptor (PD)-1 was first identified as a marker of T-cell 'exhaustion' correlating with HIV disease progression [89] . PD-1 was found to be overexpressed and associated with activation, impaired proliferation and reduced antiviral activity in memory CD8 T cells of progressors as compared with LTNP [90] . Although blockade of PD-1 was shown to increase T-cell survival [90] , PD-1 is also expressed by activated, functional T cells, and may simply be an indicator of overactivation as opposed to the cause of T-cell exhaustion [89, 91] . However, treatment of SIV-infected rhesus macaques in vivo with anti-PD-1 antibody improved CD8 T-cell proliferation, increased SIV-specific CD8 T-cell responses, decreased measurable viral load and improved survival [92 ] . These changes were seen primarily in TCR-triggered CD8 T cells, mitigating concerns about frank autoimmunity but evoking the possibility of selection of resistant viral mutants. Another inhibitory molecule, the T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), is upregulated independently of PD-1 and is also associated with T-cell dysfunction that can be partially reversed with blockade of its pathway [93 ] . The description of other inhibitory receptors on CD8 T cells that appear to coregulate T-cell exhaustion in chronic viral infections [94 ] as well as the presence of similar receptors on B lymphocytes in HIV infection [95] highlight the complexity of this field and the potential for multiple therapeutic targets.
Finally, self-reactive CD8 T cells may contribute to systemic immune activation in HIV. In mice, lymphopenia-induced proliferation can lead to loss of tolerance and autoimmunity [96] . In an intriguing study, Rawson et al. [97 ] found that HIV-infected patients have evidence of autoreactive effector CD8 T cells specific for caspase-cleaved peptides from apoptotic T cells. The number of effector CD8 T cells correlated with apoptotic CD4 T cells in HIV-infected patients and decreased with ART.
The role of coinfections
Progression and transmission of HIV disease can be altered by bacterial and viral coinfections, which may actively participate in immune activation. Genital coinfections are associated with increased susceptibility to HIV, possibly because of local activation of Langerhans' cells enhancing transfer of HIV virions to CD4 T cells over viral degradation [98] . Genital herpes simplex virus type 2 (HSV-2) infection also increases the local population of immature dendritic cells, leading to an influx of activated, CCR5
þ CD4 T-cell targets for HIV [99] . Infection with other viruses, especially adenovirus, has received attention following the STEP vaccine trial [100] . Perreau et al. [101 ] found that adenovirus immune complexes (Ad5-IC) induce dendritic cell maturation and activation in vitro, resulting in increased production of TNFa and type I interferons. Ad5-IC significantly increased in-vitro HIV infection, suggesting that adenovirus may create a 'permissive environment' for HIV infection. Mycobacterium tuberculosis increases HIV-1 viral replication and immune activation at sites of infection. Interestingly, this increase in HIV replication is most pronounced in patients with normal CD4 T-cell counts, suggesting that the synergy of the two infections may be dependent on the magnitude of immune response and activation [102] . Parasitic coinfections have also been shown to influence the natural history of HIV [103] . Rhesus macaques with schistosomiasis and SIV experience higher levels of SIV RNA than those infected with SIV alone [104] . In addition, treatment of lymphatic filariasis in HIV-infected patients led to decreases in plasma viremia, whereas treatment of Ascaris lumbricoides led to CD4 T-cell count increases [105, 106] .
HCV coinfection appears to increase the percentage of activated, less mature CD8 but not CD4 T cells [107] , and ART interruption in hepatitis B or C coinfection is associated with nonopportunistic disease-related death [108] . Further studies characterizing the interactions of HIV and chronic viral hepatitides and other latent chronic viral infections such as cytomegalovirus (CMV) and EpsteinBarr virus (EBV) will be critical in understanding their effects on HIV pathogenesis and disease prognosis.
Conclusion
Immune activation is at the crux of the complex interplay of innate and adaptive immunity throughout the asymptomatic stage of HIV infection (Fig. 2) . On the basis of current evidence, the most effective preventive or therapeutic interventions may be those that maintain low levels of immune activation with either low (the elite controllers paradigm) or variable levels of HIV viremia (the sooty mangabey paradigm). Further elucidation of factors that influence the immunologic threshold to HIV disease progression may lead to therapeutic strategies that target immune activation and could include individualized timing of ART.
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